SVP Leerink analyst Pasha Sarraf initiated CymaBay with an Outperform rating and $22 price target, telling investors in a research note that the company is demonstrating “impressive” efficacy and safety profile in PBC and pre-clinically in NASH. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.